New class of CAR T cells combat previously “untargetable” cancer drivers
The peptide-centric chimeric antigen receptors killed neuroblastoma cells in mice and could potentially expand the pool of immunotherapeutic targets.
List view / Grid view
The peptide-centric chimeric antigen receptors killed neuroblastoma cells in mice and could potentially expand the pool of immunotherapeutic targets.
Scientists revealed five proteins that cause blood vessel damage in COVID-19 patients, potentially leading to new drug targets.
Treatment with Viking Therapeutics' dual agonists resulted in mean reductions in body weight of up to 27 percent compared to semaglutide-treated animals.
Scientists have found that Hutchinson-Gilford Progeria Syndrome (HGPS) can be prevented with treatments targeting the cardiovascular system using a novel mouse model.
German, Norwegian and British scientists have identified molecular targets for therapies that could prevent breast cancer recurrence.
Scientists have developed a novel technique for the targeted clearance of senescent cells to improve treatments for ageing and other conditions.
Medicenna's IL-2 super-agonist, MDNA11, successfully induced antitumour cells in animal models, a pre-clinical study has revealed.
Researchers are identifying molecules that interact with neurolysin, a peptidase that helps protect the brain against stroke.
Researchers have used genetically engineered SARS-CoV-2 Spike proteins to boost antibodies against a range of coronaviruses in mice.
Stealth BioTherapeutic's SBT-272 improved mitochondrial motility in a murine model of amyotrophic lateral sclerosis.
Researchers have uncovered how mutations affecting RNA splicing alter cells to develop myelodysplastic syndrome (MDS).
RGX-202 was found to foil a key pathway that cancer cells rely on for energy in mice, presenting a possible new colorectal cancer therapy.
A CRISPR screening tool identified a new target for acute myeloid leukaemia with fewer side effects than current approaches.
Sinopia has been awarded a $3.3 million Fast-Track SBIR grant to fund the study for its small molecule candidate for Parkinson’s disease.
Researchers have used CRISPR and cryogenic electron microscopy to unravel the workings of two receptors involved in diseases such as cancer and COVID-19.